Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)

Area of Science:

• Genetics and Molecular Biology
• Dermatology
• Oncology

Background:

• Nevoid basal cell carcinoma syndrome (Gorlin syndrome) is a rare, autosomal dominant disorder.
• Characterized by early-onset basal cell carcinomas, keratocystic odontogenic tumors, and palmar/plantar pitting.
• Associated skeletal and developmental abnormalities are frequently observed.

Purpose of the Study:

• To elucidate the molecular pathogenesis of nevoid basal cell carcinoma syndrome.
• To understand the role of hedgehog signaling in tumor development.
• To review therapeutic strategies targeting the hedgehog pathway.

Main Methods:

• Review of genetic defects in hedgehog signaling pathway.
• Analysis of clinical features and associated abnormalities.
• Examination of therapeutic agents targeting hedgehog pathway constituents.

Main Results:

• Constitutive hedgehog pathway activity due to genetic defects drives tumor cell proliferation.
• Sporadic basal cell carcinomas also frequently exhibit hedgehog pathway aberrations.
• Vismodegib, a hedgehog pathway inhibitor, was FDA-approved in 2013 for advanced tumors.

Conclusions:

• Understanding Gorlin syndrome's molecular basis enhances knowledge of basal cell carcinoma.
• Targeted therapies for hedgehog pathway aberrations show promise.
• Further research into this pathway is crucial for treating related malignancies.